In conclusion, our results suggest that the NOS3 rs2070744 and ANGPT2 rs55633437 polymorphisms and the presence of an ANGPT2 haplotype may be capable of identifying a subset of HCC patients who are more resistant to sorafenib in terms of OS, PFS, and DCR. This evidence concerns the gene NOS3 and hepatocellular carcinoma.